www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Lung diseases
All latest versions
3 June 2025
3 December 2024
4 June 2024
5 December 2023
6 June 2023
7 December 2022
7 June 2022
7 December 2021
8 June 2021
8 December 2020
10 June 2020
10 December 2019
12 June 2019
13 December 2018
12 June 2018
9 January 2018
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by publication date
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
Asthma
Depemokimab
Formoterol / glycopyronium / budesonide
IND
COPD
Dupilumab
IND
Ensifentrine
Itepekimab
Mepolizumab
IND
Cystic fibrosis
Ivacaftor / Tezacaftor / Elexacaftor
IND
Vanzacaftor / tezacaftor / deutivacaftor
IND
Lung diseases other
Benralizumab
Patiënten met ernstige bilaterale neuspoliepen die nog steeds symptomatisch zijn ondanks de standaardbehandeling, dat wil zeggen het huidige gebruik van intra-nasale corticosteroïden (INCS) en eerdere chirurgie en/of het gebruik van systemische corticosteroïden.
IND
Extension of indication to include treatment of eosinophilic granulomatosis.
IND
Brensocatib
Ciclosporine
IND
Efzofitimod
G
Exoflo Extracellular Vesicles
Nerandomilast
Nintedanib
IND
Pamrevlumab
Riociguat
IND
Sotatercept
Tezepelumab
IND
Unknown
ARINA-1
Colistimethate Sodium
IND
Tanimilast
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
Over de Horizonscan
About the Horizon Scan
Nederlands
English